Oklahoma Proton Center, one of only 30 Proton Centers in the United States and just 5 in the southwest is offering SpaceOAR hydrogel for men with prostate cancer.
(Oklahoma City, OK) Oklahoma Proton Center, one of only 30 Proton Centers in the United States and just 5 in the southwest is offering SpaceOAR hydrogel for men with prostate cancer. The facility has partnered with two prominent local urology groups to offer the product for men receiving state of the art proton therapy treatment, the most precise form of radiation for prostate cancer. Dr. John Chung and Dr. Mark Storey are happy to offer SpaceOAR Hydrogel in combination with proton therapy to further improve cancer patient’s quality of life.
1 in 9 men in the United States will be diagnosed with prostate cancer in their lifetime, according to the American Cancer Society. Men have a number of different treatment options all of which can offer high rates of survival making the consideration of side effects an important component of the treatment decision. SpaceOAR hydrogel, distributed by Boston Scientific, is a protective spacer between the prostate and the rectum. It has been clinically proven to reduce the risk of side effects during and after radiation treatment.. The combination of proton therapy and SpaceOAR hydrogel protects men’s healthy tissue and quality of life after prostate cancer treatment.
Proton therapy has been shown to reduce the risk of GI and GU side effects such as sexual incontinence and urinary complications versus other forms of radiation treatment that deliver X-Rays such as IMRT, Cyberknife, or TomoTherapy. Additionally, data from a population analysis of over 30,000 prostate cancer patients showed that proton therapy could offer a higher overall survival for intermediate risk cancers versus IMRT.
Protons can be controlled precisely so there is less radiation of normal tissues, helping prevent serious complications and lessening the chance of secondary tumors. (1,2)
In April 2015, the Food and Drug Administration (FDA) cleared SpaceOAR hydrogel. In a prospective, randomized, multi-center clinical trial in the United States, patients treated with SpaceOAR hydrogel prior to prostate cancer radiation treatment demonstrated bowel, urinary, and sexual benefits through a median of three years of follow-up. The study found that the patients that did not receive SpaceOAR hydrogel experienced a clinically significant decline in bowel, urinary, and sexual quality of life eight times more often than patients that received SpaceOAR hydrogel. It is a minimally invasive outpatient procedure with local or general anesthesia. Patients can immediately resume their normal activities. The gel stays in place for approximately three months and is then naturally absorbed and cleared in the urine in about six months. (3,4)
For more information, visit https://www.okcproton.com/ or SpaceOAR.com.
1) Lee CT, Bilton SD, Famiglietti RM, et al. Treatment planning with protons for pediatric retinoblastoma, medulloblastoma, and pelvic sarcoma: how do protons compare with other conformal techniques? Int J RadiatOncolBiol Phys. 2005;63(2):362-372. 2) Miralbell R, Lomax A, Cella L, Scheider U. Potential reduction of the incidence of radiation-induced second cancers by using proton beams in the treatment of pediatric tumors. Int J RadiatOncolBiol Phys. 2002;54(3):824-829. 3) DA Hamstra, N Mariados, J Sylvester, et al. Continued Benefit to Rectal Separation for Prostate Radiation Therapy: Final Results of a Phase III Trial. Int J Radiat Oncol Biol Phys; 2017 Apr 1; 97(5): 976- 985 4) DA Hamstra, et al. Sexual Quality of Life Following Prostate Intensity Modulated Radiotherapy (IMRT) with a Rectal/Prostate Spacer: Secondary Analysis of a Phase III Trial. Published online: July 19, 2017 Practical Radiation Oncology. Risks associated with the implantation of SpaceOAR hydrogel: In addition to the risks associated with any medical procedure there are potential complications that may be associated with the use of the SpaceOAR System that include, but are not limited to: pain or discomfort associated with SpaceOAR hydrogel; needle penetration or injection of SpaceOAR hydrogel into the bladder, prostate, rectal wall, rectum or urethra; local inflammatory reactions; infection; injection of air, fluid or SpaceOAR hydrogel intravascularly; urinary retention; rectal mucosal damage, ulcers, necrosis; bleeding, constipation; and rectal urgency.
MEDIA CONTACT:
Julie Manning
Boston Scientific
(978) 572-6194
